WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

This marks WuXi Biologics' eighth consecutive year receiving the CDMO Leadership Award, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery ...

Revenue increased by 90.8% YoY to RMB 4,052 million Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of ...

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit ...

WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, ...

This marks WuXi Biologics' eighth consecutive year receiving the CDMO Leadership Award, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery, ...

These awards follow WuXi XDC's recent recognition at the 2024 World ADC Awards, where the company was named Best CDMO Winner for the second consecutive year, further solidifying its leadership ...